|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for EPCAM(NM_002354.2) Search again
Product ID:
HQP102051
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40, ESA, HNPCC8, KS1/4, KSA, LYNCH8, M4S1, MIC18, MK-1, MOC-31, TACSTD1, TROP1
Gene Description:
epithelial cell adhesion molecule
Target Gene Accession:
NM_002354.2(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas.
Gene References into function
- Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival.
- amplification is induced by mutations in TP53
- A 1100 bp fragment of the EpCAM promoter containing the 570 bp fragment and additional 550 bp upstream has been cloned
- Human EGP-2 antigen on epithelial cells of transgenic trachea transplants induces specific humoral and cellular immune responses, leading to mild form of obliterative airway disease. (egp-2)
- Epithelial cell adhesion molecule has a role in progression of renal cell carcinoma but is absent in clear cell carcinoma
- Ep-CAM antigen represents an attractive target for specific therapies with monoclonal antibodies or specific vaccines in patients with Ep-CAM-overexpressing gallbladder carcinoma.
- EpCAM up-regulates c-myc and induces cell proliferation
- up-regulation of DDR1, CLDN3, and epithelial cell adhesion molecule are early events in the development of epithelial ovarian cancer
- Vaccination with Ep-CAM protein may warrant further investigation as a novel therapeutic approach to colorectal cancer.
- EpCAM is vastly expressed in retinoblastoma; EpCAM reactivity was significantly higher in the invasive than the noninvasive tumors and in poorly differentiated than in well-differentiated tumors
- Ep-CAM was distributed differently in normal and various malignant colon tissues. MAbs against Ep-CAM may have diagnostic and therapeutic value to various colon carcinomas.
- EpCAM shown to be signal transducing membrane protein involved in carcinogenesis via its ability to induce genes involved in cellular metabolism and proliferation
- EpCAM expression in blood and primary and metastatic tumors is transient and dependent upon the local micro-environment
- The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context.
- MK-1 expression was found in 61% of samples.
- Tumor-specific EpCAM expression and release into the circulation may serve as effective immunotherapy in esophageal cancer patients.
- downregulation of EGP-2 promoter activity using zinc finger protein transcription factors may result in a novel anti-cancer treatment.
- claudin-7-associated EpCAM is recruited into (tetraspanin-enriched membrane microdomains) and forms a complex with CO-029 and CD44v6 that facilitates metastasis formation
- analysis of EpCAM expression in normal, non-pathological tissues
- EpCAM is a Wnt-beta-catenin signaling target gene
- The spatiotemporal expression pattern of EpCAM changes during nephrogenesis
- EpCAM and alpha-fetoprotein are expressed in hepatocellular carcinoma
- Active DNA methylation leads to sustained silencing of endogenous EpCAM expression.
- Perspectives for EpCAM-targeted apoptosis induction in cancer by EpCAM-selective bispecific antibodies. [REVIEW}
- EpCAM is strongly over-expressed in a variety of carcinomas; mutants of EpCAM that substitute asparagine198 for alanine show a decreased expression and half-life at the plasma membrane.
- Mutations in the gene for EpCAM are responsible for congenital tufting enteropathy.
- Reduced expression of EpCAM and villin is associated withn Barrett's adenocarcinoma and expression of EpCam and villin differs only between squamous epithelium and Barrett esophagus
- unmethylation of the EpCAM promoter region was associated with EpCAM overexpression; however, it was not responsible for EpCAM overexpression by itself.
- These data suggest that EpCAM is involved in signal transduction triggering several intracellular signalling pathways using tumor cell lines in colorectal and lung cancer.
- the transcripts upregulated according to disease progression were associated with signaling pathway/transcription, including tumor-associated calcium signal transducer 1 and chemokine ligand 19, and with cell communication, such as collagen.
- EpCAM (TACSTD1) gene mutations occur in Lynch Syndrome and result in methylation of the 3 located msh2 gene, which is involved in mismatch repair.
- Patients from Dutch and Chinese families with MSH2-deficient tumors carrying heterozygous germline deletions of the last exons of TACSTD1, a gene directly upstream of MSH2 encoding Ep-CAM, are described.
- EpCAM is frequently over-expressed on cancer initiating cells in various tumour entities
- EpCAM signals to the cell nucleus following regulated intramembrane proteolysis and nuclear translocation of its intracellular domain (EpICD). EpICD on its own (26aa) is highly tumourigenic in SCID mice.
- Here we show that regulated intramembrane proteolysis activates EpCAM as a mitogenic signal transducer in vitro and in vivo.
- Data are the first demonstration that wild-type p53 protein binds to a response element within the EpCAM gene and negatively regulates EpCAM expression, and transcriptional repression of EpCAM contributes to p53 control of breast cancer invasion.